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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comand frequencies simulating various physiological conditions at the start and after 100
million cycles.
Results: Analysis was performed with transapical Jenavalve prostheses (27mm)
implanted in circular annuli (n¼3) or annuli with 0.84 eccentricity (n¼3). Hydrody-
namic testing showed no signiﬁcant difference in valve performance with regard to the
average regurgitation volume under both conditions at the start [circular: 4.69%
0.20%; oval: 4.81%2.05% of total stroke volume; p¼n.s.] Interestingly after a
durability test of 100 million cycles hydrodynamic testing showed a slightly reduced
average regurgitation volume in the oval annulus [circular: 5.53%0.19%; oval:
3.59%0.39% of total stroke volume; p¼n.s.]. Macroscopic analysis and histology
revealed no difference between valve leaﬂets of the two groups.
Conclusions: This is the ﬁrst experimental in vitro durability study demonstrating no
signiﬁcant difference in valve performance and regurgitation volume for a percuta-
neous valve implanted in an eccentric annulus.
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Background: The aim of this study is to compare the clinical outcomes after trans-
catheter aortic valve implantation (TAVI) with the Edwards SAPIEN/SAPIEN XT
transcatheter heart valve (ESV) versus the Medtronic CoreValve (MCV) in Asian
countries.
Methods: The data from databases of 3 Asian centers were pooled and analyzed.
Study objectives were Valve Academic Research Consortium outcomes at 30 days
and 1 year. In total, 185 patients were included: 86 (46.5%) treated with the ESV and
99 (53.5%) with the MCV.
Results: Previous PCI, previous CABG and peripheral artery disease were more
frequent in ESV group but aortic annulus area and perimeter measured by MDCT
were larger in MCV group. There were no differences in baseline echocardiographic
ﬁndings and calciﬁcation grade. Device success occurred in 78 of 86 patients
(90.7%) in ESV group and 74 of 99 (74.7%) patients in MCV group (relative risk
[RR],1.21; 95% conﬁdence interval [CI]: 1.40 to 7.75;p¼ 0.005).This was attributed
to a signiﬁcantly lower frequency of residual more-than-mild aortic regurgitation
(7.2% vs. 16.0%; RR, 0.45; 95% CI 0.90 to 6.61; p ¼ 0.07) and the less frequent
need for implanting more than 1 valve (0% vs. 10.1%;p ¼ 0.002). All-cause
mortality at 30 days was 4.7% in ESV group and 2.0% in MCV group (RR, 2.35;
95% CI, 0.42 to 13.33; p ¼ 0.42). Stroke, bleeding and vascular complications were
not signiﬁcantly different, and the combined safety end point occurred in 14.0% in
ESV group and 10.1% in MCV group (RR, 1.39; 95% CI, 0.59 to 3.53; p ¼ 0.42).
Placement of a new permanent pacemaker was less frequent in the ESV group
(1.2% vs. 22.2%, p< 0.001). At 1 year, there were no difference in all-cause
mortality (8.6% vs. 8.5%; hazard ratio [HR], 0.77; 95% CI, 0.28 to 2.23; p ¼ 0.61)
and combined efﬁcacy endpoint (15.1% vs. 22.2%; RR, 0.68; 95% CI, 0.29 to 1.33;
p ¼ 0.22).
Conclusions: Among patients with aortic stenosis undergoing TAVI in Asian coun-
tries, the use of ESV resulted in a greater rate of device success than use of MCV,
however combined safety endpoint at 30 days, and all-cause mortality and combined
efﬁcacy endpoint at 1 year were similar between 2 groups.
TCT-753
Efﬁcacy and Feasibility of On-pump Transcatheter Aortic Valve Implantation
in Patients with Severely Decompensated Heart Failure
Koichi Maeda1, Toru Kuratani1, Kei Torikai1, Isama Mizote1, Yasuhiro Ichibori1,
Satoshi Nakatani1, Yasushi Sakata1, Koichi Toda1, Yoshiki Sawa1
1Osaka University Graduate School of Medicine, Suita, Osaka
Background: Although transcatheter aortic valve implantation (TAVI) has widened
the indication for the treatment of aortic valve stenosis (AS), there is still a group of
patients considered ‘extremely high-risk’, including those with severely decom-
pensated heart failure. The aim of this study is to evaluate the early results of TAVI
under cardiopulmonary bypass support (CPS) (on-pump TAVI) in patients with
severely decompensated heart failure.
Methods: Among 157 cases from October 2009 through April 2014, twelve patients
(7.6%) were treated by on-pump TAVI using SAPIEN/SAPIEN XT. Mean age was
816 years and left ventricular ejection fraction (LVEF) was signiﬁcantly low
(337). Ten patients (83%) were dependent on catecholamine support and one
patient (8.3%) was required CPS preoperatively. Mean preoperative BNP was
signiﬁcantly high (1562 pg/ml). EuroSCORE was 6225% and STS score was
2723%.B220 JACC Vol 64/11/Suppl B j SepResults: Urgent procedure was required in three cases (25%). Transapical procedure
was preformed in three cases (25%). Procedural success was 100% and CPS was
removed in operating room in all patients (pump time, median: 13 minutes). One
patient was died from coronary event 3 postoperative day. There were no thrombo-
embolic and neurologic complications. Ten patients (83%) were discharged to home.
LVEF at 1-month was signiﬁcantly improved (49%, p< .05). The 30-day mortality
was 8.3% and survival at 6- and 12-months were 91% and 78%, respectively (mean
follow-up period, 332277 days).
Conclusions: We achieved satisfactory early and short-term outcomes of on-pump
TAVI. On-pump TAVI may become the standard therapy to treat aortic valve stenosis
in the presence of severely decompensated heart failure.
TCT-754
Predictors For Tissue Embolization During Transcatheter Aortic Valve
Implantation
Nicolas M. Van Mieghem1, Peter De Jaegere2
1Erasmus MC, Rotterdam, Netherlands, 2Thoraxcenter, Erasmus Medical Center,
Rotterdam, Rotterdam, Netherlands
Background: Cerebrovascular embolization is frequent during Transcatheter Aortic
Valve Implantation (TAVI). The aim of this study was to identify variables associated
with tissue embolization during TAVI.
Methods: A total of 82 patients underwent TAVI with a dual ﬁlter– based embolic
protection device (Montage Dual Filter System, Claret Medical, Inc) deployed in the
brachiocephalic trunk and left common carotid artery. Both balloon expandable and
self-expanding transcatheter heart valves (THV) were used. After TAVI the ﬁlters
were retrieved and sent for histopathologic analysis.
Results: Overall, debris was captured in 86% of patients. Captured material varied in
size from 0.1 to 9.0 mm. Thrombotic material was found in 74% of patients and tissue-
derived debris in 63%. Tissue-derived debris was found more often with balloon
expandable THV (79% vs. 56%, p ¼ 0.05). The dislodged material corresponded best
with dislodged tissue from the native aortic valve leaﬂets, aortic wall or left ventricular
myocardium. Balloon-expandable THV (adjusted OR: 12.100; 95% CI 1.925-76.040,
p ¼ 0.008) and cover index (adjusted OR: 1.151, 95% CI 1.015-1.307, p ¼ 0.029)
were independent predictors for tissue embolization by multivariable logistic regres-
sion analysis.
Conclusions: Debris is captured with ﬁlter-based embolic protection in the vast
majority of patients undergoing TAVI. Tissue derived material is found in 63% of
cases and is correlated with the use of balloon expandable systems and more
oversizing.
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Background: Trancatheter Aortic Valve Implantation (TAVI) is an option to treat
pure severe aortic regurgitation (PSAR) in patients at high surgical risk. We hereby
report the 3-year follow-up (3-y FU) of patiens with inoperable PSAR treated in our
Institute using Medtronic CoreValve prosthesis.
Methods: Aortic valve sizing was assessed on 3 dimensional-CT scan considering
perimeter, area, major and minor orthogonal annular diameter. An oversizing pros-
thesis with respect of annular perimeter was used. We developed a size table (see
below) to choose the right valve dimension. Sixteen pts with PSAR underwent TAVI
with CoreValve prosthesis (mean age 84+2,6; mean L-Euroscore 33%)Results: A procedural success has been reached using a single valve in 13 pts. In
these pts we observed an improved functional capacity and no death at a 3-y FU. In
one case a second valve deployment (CoreValve 29 mm in Core-Valve 31 mm) was
necessary to reduce the peri-leak severe aortic regurgitation obtaining a ﬁnal mod-
erate grade of aortic regurgitation. In this case we observed a worsening of NYHA
class after 1-y FU and frequent re-hospitalizations for congestive heart failure at 3-y
FU. In 2 cases conversion to emergency open surgery and aortic valve replacement
was required due to residual severe aortic regurgitation despite a second valve
deployment. These 2 pts died 1 year after the procedure (one from infective endo-
carditis and one from acute pulmonary edema). A new permanent PM implantation
was necessary in 7 pts.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: Our 3-y FU data reinforce the concept that TAVI should be avoided when
the native annulus perimeter is> 8,5 cm. In this context the larger CoreValve available
(31 mm) cannot be use as oversizing prosthesis. To the contrary when an oversizing
valve prostheis can be used acceptable results are achieved. In this setting of pts TAVI
showed no death, and good clinical outcomes that were sustained at 3-y FU.
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Background: The incidence and prognostic impact of late bleeding complications
(LBC) after TAVR are unknown. We sought to identify the incidence, predictors, and
prognostic impact of LBC (30 days) after TAVR.
Methods: Clinical and echocardiographic outcomes of patients who underwent
TAVR within the randomized cohorts and continued access registries in the PART-
NER trial were analyzed after stratifying by the occurrence of LBC. Predictors of LBC
and its association with 30-day to 1-year mortality were assessed.
Results: Among 2,401 patients who underwent TAVR and survived to 30 days, LBC
occurred in 142 (5.9%) at median time of 132 [71, 230] days after the index procedure.
Gastrointestinal (n¼58; 40.8%), neurologic (n¼22; 15.5%), and traumatic falls
(n¼11; 7.8%) were identiﬁed as the most frequent types of LBC. Independent pre-
dictors of major LBC were the presence of atrial ﬁbrillation or ﬂutter (AF) at baseline
or 30 days, the presence of moderate/severe paravalvular leak (PVL) at 30 days, the
presence of low hemoglobin at baseline, and greater left ventricular mass at 30 days.
LBC was identiﬁed as a strong independent predictor of mortality between 30 days
and 1 year (adjusted HR 3.91, 95% CI [2.67, 5.71], p< 0.001). The presence of AF,
especially when LBCs occurred, was associated with a poor prognosis and high rate of
mortality.
Conclusions: LBC after TAVR were frequent and associated with increased mor-
tality. A better-individualized and risk-adjusted antithrombotic therapy after TAVR is
urgently needed in this high-risk population.TCT-757
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Background: Transcatheter aortic valve implantation is the contemporary treatment
of choice for high/prohibitive surgical risk patients with severe aortic stenosis.
Methods: Outcomes of consecutive 275 (61% female) severe aortic stenosis patients,
treated with TAVI and followed up to 3 years (mean 702 days), were analyzed and
reported according to the Valve Academic Research Consortium 2 deﬁnitions. The
primary end point was death from any cause.
Results: This patient group (60% women) was characterized by advanced age (mean
81.76.8), high mean log-EuroScore ¼ 19.112 and STS score ¼ 8.15.
The Medtronic-CoreValve device was utilized in 195(71%) and the Edwards-
Sapien device in 80(29%) of patients. The trans-femoral, trans-axillar, trans-apical,JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Vatrans-aortic and retroperitoneal route were used in 224, 20, 29, 1 and 1 patients;
respectively. Procedural success was 97.1%. One month, 1 year, 2 and 3 years survival
rates were 97%, 91%, 85% and 70%; respectively. Peri-procedural\in-hospital stroke
was diagnosed in 9 (3.2%) patients. Permanent pacemaker was required in 40 (14.5%)
patients: (36 cases in CoreValve and 4 in Sapien valves). Signiﬁcant paravalvular leak
(moderate) was noted in 22 (8%) patients. After the procedure, mean valve gradients
decreased from 51.216 to 8.17 (p< 0.001). Symptomatic improvement was
evident during follow up, having 98% of patients in NYHA-FC I or II.Conclusions: The current report signiﬁes that catheter-based treatment of mostly
elderly patients with severe aortic stenosis is feasible, safe and associated with
satisfactory long-term outcomes.
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Background: Acute kidney injury (AKI) is a serious complication after transcatheter
aortic valve implantation (TAVI) and patients with preexisting renal impairment seem
to be especially prone to AKI. Very few data exist about the impact of invasive
hemodynamics on the occurrence of AKI after TAVI. The objectives oft the study
were (i) to determine the incidence and predictive factors for AKI with emphasis on
invasive hemodynamics, and (ii) to examine short-and longterm outcome of these
patients.
Methods: A total of 540 patients (mean age: 80.27.1, logES: 24.517.9%) un-
dergoing TAVI were included in the study. Patients were divided into three groups
according to their glomerular ﬁltration rate (GFR) before TAVI (A: normal renal
function i.e. GFR  60ml/min; B: impaired renal function i.e. GFR 30-59 ml/min; C:
severe impaired renal function i.e. GFR < 30 ml/min). Renal function and survival
were recorded over 12 months.
Results: Overall 30-day mortality was 10.2 % and 12-month mortality was 21.5%.
Subgroup analysis showed signiﬁcant differences between the groups with regard to
30-day-mortality (A: 5.4%, B: 9.0%, C: 25.0%) and 12-month mortality (A: 15.0%, B:
32.0%, C: 49%). AKI occurred in 30 patients (5.6%), of which the majority were
patients of group B (16 patients). 30-day-mortality of patients with AKI was 53.3%
(16 patients) and 12-month-mortality was 73.3% (22 patients). Systemic arterial
pressures were signiﬁcantly higher before and after TAVI in patients without AKI
compared to patients with AKI, whereas preprocedural and postprocedural pulmonary
and right atrial pressures did not differ between both groups. Predictive factors forlvular disease - Aortic: TAVR B221
